1. Prevention of allergic asthma through Der p 2 peptide vaccination
Gregory Bouchaud, PhD, Faouzi Braza, PhD, Julie Chesné, PhD, David Lair, MS, Kuan-Wei Chen, PhD, Camille Rolland-Debord, MD, Dorian Hassoun, MS, Tiphaine Roussey-Bihouée, MD, Marie-Aude Cheminant, BS, Sophie Brouard, PhD, Marie Bodinier, PhD, Susanne Vrtala, PhD, Antoine Magnan, MD 
Journal of Allergy and Clinical Immunology 
Volume 136, Issue 1, Pages e1 (July 2015)
DOI: /j.jaci
Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2. Fig 1
Derp 2.1 exhibits therapeutic potential in a mouse model of Dermatophagoïdes pteronyssinus–induced asthma. A, Schematic representation of the HDM antigen–allergic model. B, Penh values (n = 8-12 mice per group). C, Total BAL cell numbers (n = 8-12 mice per group). D, BAL eosinophil values (n = 8-12 mice per group). E, BAL neutrophil values (n = 8-12 mice per group). ***P < .001, **P < .01, and *P < .05.
Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci )
Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3. Fig 2
Vaccination with Der p 2.1 normalizes lung function and influences airway inflammation. A and B, Resistance and elastance values obtained by invasive measurements (n = 8-12 mice per group). C, BAL levels of chemokines after vaccination (n = 4-6 mice per group). D, T-cell responses in lung mucosa (n = 5-8 mice per group). E, Serum levels of Der p 2–specific IgE, IgG1, and IgG2a after Der p 2.1 vaccination (n = 5 mice per group). F, Penh values obtained after vaccination with Der p 2.1 in mouse model of Dermatophagoïdes farinae–induced asthma (n = 8-12 mice per group). KC, Keratinocyte derived chemokine; MCP-1, monocyte chemoattractant protein-1; ***P < .001, **P < .01, and *P < .05.
Journal of Allergy and Clinical Immunology  , e1DOI: ( /j.jaci )
Copyright © 2015 American Academy of Allergy, Asthma & Immunology Terms and Conditions